What question did this study set out to answer?

Determine whether human astrocytoma cells express functional, specific receptors for atrial natriuretic peptide (ANP) and whether peptide binding alters cyclic GMP levels.

May 1, 1988Journal of Endocrinology

Specific binding of atrial natriuretic peptide increases cyclic GMP levels in human astrocytoma cells

Q: What is the clinical evidence from this study?

Population: Human astrocytoma cell line G-CCM. Intervention: Atrial natriuretic peptide (ANP) vs. Unrelated peptides (angiotensin II, vasopressin, bradykinin). Primary outcome: Intracellular level of cyclic GMP.

View Full Paper

Ask AI

Bookmark

Key result

Human atrial natriuretic peptide stimulated human astrocytoma cells to increase their intracellular level of cyclic GMP in a time- and dose-dependent manner.

Key Points

Determine whether human astrocytoma cells express functional, specific receptors for atrial natriuretic peptide (ANP) and whether peptide binding alters cyclic GMP levels.
Assessed competitive receptor binding on clone D384 human astrocytoma cells (derived from cell line G-CCM) using human ANP, rat ANP, structural peptide analogs, and unrelated peptides (angiotensin II, vasopressin, and bradykinin).
Quantified intracellular cyclic GMP accumulation following human ANP stimulation across varying time points and peptide concentrations up to 1 µmol/l.
Identified specific high-affinity ANP binding sites with a dissociation constant (Kd) of 100 pmol/l that bound human and rat ANP equally.
Unrelated peptides (angiotensin II, vasopressin, bradykinin) showed no competition, while ANP fragments lacking terminal residues or the internal disulfide bond exhibited reduced or absent binding.
Human ANP stimulated intracellular cyclic GMP production in a time- and dose-dependent manner, approaching maximal stimulation at 1 µmol/l.

Structured PICO

Population

Clone D384 derived from the human astrocytoma cell line G-CCM

Intervention

Atrial natriuretic peptide (ANP) (human and rat)

Comparator

Unrelated peptides (angiotensin II, vasopressin, bradykinin) and ANP variants (missing C- or N-terminal residues or internal -S-S-bond)

Outcome

Specific high-affinity binding sites and intracellular cyclic GMP levelssurrogate

The identification of specific ANP binding sites on human astrocytoma cells that increase cGMP supports a functional role for ANP in the brain and neurone-glia communication.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

No immediate clinical implications; hypothesis-generating for ANP signaling in glial cells.

Cite This Study

Lyall et al. (1988) studied Human astrocytoma cell line G-CCM. Atrial natriuretic peptide (ANP) vs. Unrelated peptides (angiotensin II, vasopressin, bradykinin) was evaluated on Intracellular level of cyclic GMP. Human atrial natriuretic peptide stimulated human astrocytoma cells to increase their intracellular level of cyclic GMP in a time- and dose-dependent manner.

synapsesocial.com/papers/6a9b2e49163176090bd3a89a https://doi.org/10.1677/joe.0.1170315

View Full Paper

Ask AI

Bookmark

Specific binding of atrial natriuretic peptide increases cyclic GMP levels in human astrocytoma cells

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Specific binding of atrial natriuretic peptide increases cyclic GMP levels in human astrocytoma cells

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider